|
|
Volumn 17, Issue 6, 2003, Pages 623-
|
|
Treatment of bullous pemphigoid: What's new?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIGEN;
AUTOANTIBODY;
AZATHIOPRINE;
CELL PROTEIN;
CHLORAMBUCIL;
CORTICOSTEROID;
DESMOPLAKIN;
HEMIDESMOSOMAL PROTEIN;
IMMUNOGLOBULIN;
IMMUNOMODULATING AGENT;
METHOTREXATE;
METHYLPREDNISOLONE;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
NICOTINAMIDE;
PREDNISOLONE;
TETRACYCLINE;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ANTIBODY TITER;
CLINICAL TRIAL;
DRUG COMBINATION;
DRUG COST;
DRUG EFFICACY;
DRUG POTENCY;
DRUG RESPONSE;
DRUG SAFETY;
EDITORIAL;
FEMALE;
HOSPITALIZATION;
HUMAN;
MALE;
METHODOLOGY;
MORTALITY;
MULTIMODALITY CANCER THERAPY;
PEMPHIGOID;
PLASMAPHERESIS;
PRIORITY JOURNAL;
PROGNOSIS;
RISK BENEFIT ANALYSIS;
SURVIVAL RATE;
TREATMENT OUTCOME;
AGED;
COMBINED MODALITY THERAPY;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
PEMPHIGOID, BULLOUS;
PLASMAPHERESIS;
PROGNOSIS;
SEVERITY OF ILLNESS INDEX;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 0242708714
PISSN: 09269959
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1468-3083.2003.00713.x Document Type: Editorial |
|
Times cited : (2)
|
|
References (3)
|
